Atsuhiko Ishida

Dr. Atsuhiko Ishida

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2015 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
THTetsuo Hirano
Tetsuo Hirano
RYRyoko Yoshikawa
Ryoko Yoshikawa
HHHironori Harada
Hironori Harada
YHYuka Harada
Yuka Harada
AIAtsuhiko Ishida
Atsuhiko Ishida
TYTakeshi Yamazaki
Takeshi Yamazaki
Accumulating evidence suggests that some long noncoding RNAs (lncRNAs) are involved in certain diseases, such as cancer. The lncRNA, CCDC26, is related to childhood acute myeloid leukemia (AML) because its copy number is altered in AML patients. We found that CCDC26 transcripts were abundant in the nuclear fraction of K562 human myeloid leukemia cells. To examine the function of CCDC26, gene knockdown (KD) was performed using short hairpin RNAs (shRNAs), and four KD clones, in which CCDC26 expression was suppressed to 1% of its normal level, were isolated. This down-regulation included suppression of CCDC26 intron-containing transcripts (the CCDC26 precursor mRNA), indicating that transcriptional gene suppression (TGS), not post-transcriptional suppression, was occurring. The shRNA targeting one of the two CCDC26 splice variants also suppressed the other splice variant, which is further evidence for TGS. Growth rates of KD clones were reduced compared with non-KD control cells in media containing normal or high serum concentrations. In contrast, enhanced growth rates in media containing much lower serum concentrations and increased survival periods after serum withdrawal were observed for KD clones. DNA microarray and quantitative polymerase chain reaction screening for differentially expressed genes between KD clones and non-KD control cells revealed significant up-regulation of the tyrosine kinase receptor, KIT, hyperactive mutations of which are often found in AML. Treatment of KD clones with ISCK03, a KIT-specific inhibitor, eliminated the increased survival of KD clones in the absence of serum. We suggest that CCDC26 controls growth of myeloid leukemia cells through regulation of KIT expression. A KIT inhibitor might be an effective treatment against the forms of AML in which CCDC26 is altered.

1 January 2015 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
YIYasuhiro Ishihara
Yasuhiro Ishihara
TTTakuya Takemoto
Takuya Takemoto
AIAtsuhiko Ishida
Atsuhiko Ishida
TYTakeshi Yamazaki
Takeshi Yamazaki
Steroid hormones synthesized in and secreted from peripheral endocrine glands pass through the blood-brain barrier and play a role in the central nervous system. In addition, the brain possesses an inherent endocrine system and synthesizes steroid hormones known as neurosteroids. Increasing evidence shows that neuroactive steroids protect the central nervous system from various harmful stimuli. Reports show that the neuroprotective actions of steroid hormones attenuate oxidative stress. In this review, we summarize the antioxidative effects of neuroactive steroids, especially 17β-estradiol and progesterone, on neuronal injury in the central nervous system under various pathological conditions, and then describe our recent findings concerning the neuroprotective actions of 17β-estradiol and progesterone on oxidative neuronal injury induced by organometallic compounds, tributyltin, and methylmercury.

19 April 1999 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
YTYoshiro Tatsu
Yoshiro Tatsu
YSYasushi Shigeri
Yasushi Shigeri
AIAtsuhiko Ishida
Atsuhiko Ishida
KIKameshita Isamu
Kameshita Isamu
HFHitoshi Fujisawa
Hitoshi Fujisawa
NYNoboru Yumoto
Noboru Yumoto

1 February 2018 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
AIAtsuhiko Ishida
Atsuhiko Ishida
NSNoriyuki Sueyoshi
Noriyuki Sueyoshi
IKIsamu Kameshita
Isamu Kameshita

2 June 2008 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
AIAtsuhiko Ishida
Atsuhiko Ishida
NSN Sueyoshi
N Sueyoshi
YSY Shigeri
Y Shigeri
IKI Kameshita
I Kameshita
Multifunctional Ca2+/calmodulin-dependent protein kinases (CaMKs) play pivotal roles in intracellular Ca2+ signaling pathways. There is growing evidence that CaMKs are involved in the pathogenic mechanisms underlying various human diseases. In this review, we begin by briefly summarizing our knowledge of the involvement of CaMKs in the pathogenesis of various diseases suggested to be caused by the dysfunction/dysregulation or aberrant expression of CaMKs. It is widely known that the activities of CaMKs are strictly regulated by protein phosphorylation/dephosphorylation of specific phosphorylation sites. Since phosphorylation status is balanced by protein kinases and protein phosphatases, the mechanism of dephosphorylation/deactivation of CaMKs, corresponding to their 'switching off', is extremely important, as is the mechanism of phosphorylation/activation corresponding to their 'switching on'. Therefore, we focus on the regulation of multifunctional CaMKs by protein phosphatases. We summarize the current understanding of negative regulation of CaMKs by protein phosphatases. We also discuss the biochemical properties and physiological significance of a protein phosphatase that we designated as Ca2+/calmodulin-dependent protein kinase phosphatase (CaMKP), and those of its homologue CaMKP-N. Pharmacological applications of CaMKP inhibitors are also discussed. These compounds may be useful not only for exploring the physiological functions of CaMKP/CaMKP-N, but also as novel chemotherapies for various diseases.

1 February 1997 in Analytical Biochemistry
Verified
Journal Article
Closed access
IKIsamu Kameshita
Isamu Kameshita
AIAtsuhiko Ishida
Atsuhiko Ishida
SOSachiko Okuno
Sachiko Okuno
HFHitoshi Fujisawa
Hitoshi Fujisawa